Heron Therapeutics, Inc. (HRTX) Earnings Call Transcript & Summary
November 3, 2021
Earnings Call Speaker Segments
David Szekeres
executiveThanks, Gigi. Good afternoon, everybody, and I appreciate you being here. Joining me on this call from Heron are Barry Quart, our Chief Executive Officer and Chairman; John Poyhonen, President and Chief Commercial Officer; and Kimberly Manhard, Executive Vice President of Drug Development and a Board Director. If you're on the conference call, the slides are available through webcast, and you can also get them by visiting the Investor Relations page on our website once today's call wraps up. Before we get started, I want to remind everyone that forward-looking statements will be part of this call, covering inherent future expectations, plans, prospects, corporate strategy and performance, and these constitute forward-looking statements for purposes of the safe harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from what those forward-looking statements indicate due to various important factors, including the ones discussed in our filings with the SEC. Also, any forward-looking statements reflect our views only as of the date of this webcast and shouldn't be relied upon as representing our views as of any later date. We specifically disclaim any obligations to update such statements. Now I'll hand the call over to Barry.
Barry Quart
executiveThanks, David. Hello, everybody, and I appreciate you being with us. These past few months rank among the most significant and fruitful stretches in the history of this company. We got ZYNRELEF off the ground in the United States for post-op pain — that's our first offering in the acute care franchise and our third commercial product in total — and our attention is on building long-term growth in that franchise around ZYNRELEF. P&T committee approvals have gone really well, which is quite heartening for our debut quarter of launch. At this point, our priority is broadening the label and the commercial potential for ZYNRELEF, and I'll get into that shortly. We're likewise working to steady sales in the oncology care franchise across this year and to deliver modest growth in the next one. Our conversations with the FDA went well as we sought to support label expansion for ZYNRELEF and to boost product supply. Two sNDAs for expanding the ZYNRELEF label got the FDA's agreement. We sent the first supplemental NDA to the FDA at the close of September, and it should widen the label to cover foot and ankle, small to medium, open abdominal, and lower extremity total joint arthroplasty surgical procedures. The agency likewise signed off on what would go into the second supplemental NDA, to broaden — to broadly cover orthopedic and soft tissue surgical procedures. Per the FDA, studies for that second sNDA are underway already. Pharmacokinetics and safety serve as the endpoints in those studies; showing efficacy isn't needed to win approval. Our plan is to file that second sNDA during the back half of 2022. Should it be cleared, this wide indication would span more than 14 million target procedures. On top of that, the FDA granted approval for our manufacturing supplement adding a second supplier of the proprietary polymer we make. That green light is a vital move toward being able to produce millions of doses each year and to bring the cost of goods down substantially; it came through in less than 4 months, and along with upcoming label expansions, it will let us deliver a highly effective non-opioid postoperative pain drug to millions of patients each year. All in all, the quarter was superb for Heron. As an organization, we're still strongly positioned, and we look forward to hitting more key commercial and corporate milestones over the next year. With that, I'll hand things to John so he can walk through our commercial portfolio. John?
John Poyhonen
executiveThanks, Barry. I'm genuinely thrilled to walk you through what happened on the commercial side in our third quarter. ZYNRELEF has gotten out of the gate quickly even though the market is facing some pretty serious obstacles. In my remarks, I'll begin by covering several important metrics that show the early traction we're gaining with the ZYNRELEF launch, and then I'll close with an update on how our Oncology Care business is performing commercially. ZYNRELEF has enjoyed a robust beginning in this, its first quarter on the market, posting net product sales of $2.1 million. We've already secured wide access across the country for stocking within the distribution channel, which lets us get product to ordering accounts quickly. We work with 4 full-line wholesalers: ABC, Cargo, McKesson and Morris & Dickson. To date, 68 stocking distribution centers have moved ZYNRELEF, and 50% of those DCs have placed reorders; on top of that, we use 10 specialty distributors to serve ambulatory surgical centers, or ASC. So far, 10 stocking distribution centers have moved ZYNRELEF, and 60% of those DCs have placed reorders for the product. Slide number seven updates the slide we presented back in May on our ZYNRELEF FDA approval conference call, covering successful hospital launches. As you can see, we've now included ANJESO's first five quarters. To be fully transparent, their first quarter captured just one month of sales. We've also included ZYNRELEF's first quarter of net product sales. We believe we're off to a terrific start and remain confident that ZYNRELEF's total net product sales will beat EXPAREL's over the first 6-quarter period. Slide number eight shows how quickly ZYNRELEF is gaining formulary access. As of the close of October, we hold 126 formulary approvals. The ongoing effect of COVID-19 shouldn't be underestimated. We're certain ZYNRELEF would have already been added to more formularies if COVID-19 weren't pushing P&T committee decisions back. Still, among the accounts that are actually making P&T decisions, more than 91% of hospital P&T committees are putting ZYNRELEF on formulary. Notably, 55% of our formulary approvals permit unrestricted use of ZYNRELEF. We expect the wider label indications anticipated from the supplemental NDA we filed recently will undoubtedly spur greater use at these hospitals and also make a meaningful difference at those hospitals that have approved ZYNRELEF with restrictions tied to the indicated procedures. The rest of 2021 will be a pivotal stretch for formulary access, with more than 150 additional P&T committees set to review ZYNRELEF before the year ends; we'll keep watching closely for how COVID might affect the timing of P&T committee schedules. Thankfully, whenever we've seen delays in P&T committee schedules, they've usually run 30 to 60 days. Within the hospital market, winning a P&T committee approval and a formulary spot matters a great deal, yet that's only the start. It's worth remembering that a lot of hospitals additionally need a medical executive sign-off, establishment of CPOE or Computerized Physician Order Entry, and then pharmacy stocking before the product can be used in patients. On slide nine, we're looking at how many distinct accounts placed orders in the first three months after launch, drawing on Symphony Health data. With ZYNRELEF, we're picking up considerable momentum during that initial 3-month window, reaching 160 unique ordering accounts. Our view is that this stacks up quite well against the EXPAREL launch back in April of 2012, which came with a broad label indication and took place before COVID could affect the outcome. Over the last 18 months, three nonopioid analgesics — ZYNRELEF, Xerocole and <<inaudible>> — have entered the market amid the COVID-19 era. The count of unique ordering accounts for ZYNRELEF is more than 4 times that of whichever competitor comes closest. On top of that, 50% of accounts placed reorders within the first three months for ZYNRELEF, which is the highest reorder rate among the four products this analysis benchmarks. Though these early gene relief figures are solid, we remain far from content, and we'll keep adding unique ordering accounts while building further momentum and more formulary-approved accounts as we move through the fourth quarter. October is already showing gains on both of those fronts, and we anticipate additional unique ordering account growth as further formulary approvals come through for the rest of the quarter; on the reimbursement coverage side, we've also witnessed outstanding early results across both commercial and Medicaid payers; for ZYNRELEF we've secured separate reimbursement outside the surgical bundle already, along with more than 88 million covered lives in ASCs, and in certain instances we also have separate reimbursement within the hospital outpatient setting. For a new postoperative pain drug, we consider this coverage to be unprecedented. One central element of how we set pricing applies to procedures lacking separate reimbursement. Because ZYNRELEF carries a lower acquisition cost, customers benefit in every setting of care where reimbursement may fall under the surgical bundle payment. Our pass-through application is still under CMS review, and we have every expectation of pass-through in the New Year. Through December 31, 2021, CMS reimburses ZYNRELEF at 95% and of average wholesale price, a highly favorable rate for Medicare patients receiving care in the outpatient setting. We got some excellent news yesterday. CMS released the calendar year 2022 outpatient prospective payment system final rule, and it granted ZYNRELEF a specific SCO C9088 enabling separate reimbursement in the ASC setting of care starting January 1, 2022. The impact here will be meaningful, because ZYNRELEF will keep receiving reimbursement in ASCs even past the customary 3-year pass-through window. For the rest of the year, we have four key priorities with ZYNRELEF, and every one of them centers on extending the strong foundation we established in Q3. First, we'll keep growing usage and new formulary-approved accounts through pull-through activities, including in services, so that the first experience is a positive one and surgeons become loyal users. What we've seen and heard from physicians so far outpaces even the results from our clinical trials, which is enormously exciting for both patients and surgeons. As a matter of fact, several orthopedic surgeons have been impressed enough by ZYNRELEF's results that they've already used it in more than 100 TKA cases since launch. Next, we'll keep prioritizing securing formulary approval at the hospital level, both for Integrated Delivery Networks, or IDNs, so we can grow more distinctive accounts that place repeat orders regularly. The fact that 91% of hospitals have granted formulary approval shows how much unmet need exists in the market, and it makes us very optimistic about what lies ahead. Third, we'll keep broadening reimbursement coverage from commercial payers and employers, which delivers a financial advantage to our customers and opens wider patient access to non-opioid options. When it comes to commercial payers covering ZYNRELEF outside the surgical bundle, the decisive element has been showing, through our clinical trials, that it is superior to bupivacaine, the standard of care. ZYNRELEF holds the distinction of being the first and only local anesthetic that the FDA has designated as extended release, delivering pain reduction for as long as 20 — for as long as 72 hours. The news yesterday that CMS has assigned ZYNRELEF a specific C-code allowing separate reimbursement in ASCs marks yet another encouraging development in this effort. Last, we have no doubt that the solid foundation of ZYNRELEF business will leave us well positioned to broaden usage once the FDA grants approval for our new label indications, which Barry already walked through earlier. At this point, I'd like to change direction and go over the third quarter results for our Oncology Care franchise.
John Poyhonen
executiveFor the CIMB franchise products, Q3 delivered yet another strong showing, with net sales reaching $21.1 million — a 6% gain versus the previous year. During that same quarter, though, we ran into certain headwinds tied to COVID's effect, which reduced cancer screenings and caused fewer new patients to begin treatment. In addition, CMS' oncology care model, along with its other value-based contracts, helps community oncology practices shift toward lower-cost generic and biosimilar options. And finally, rival products were keeping either high value or net cost recovery for oncology practices through aggressive pricing. Even so, we think both <<inaudible>> sales are set to grow within the clinic segment starting in 2022. Two main factors underlie this view. First, generic fast profit and ASP reimbursement dropped 27% compared with the previous quarter, falling to $36.45 in Q4 '21, and that makes CINVANTI's worth to oncology practices far more appealing in 2022. Second, because of COVID, a backlog of oncology patients has built up, and we believe that since both products work in HEC as well as the majority of MEC regimens, once new patients come back into the system for treatment, those new patient starts will generate growth chances for both of our products. For the fourth quarter of 2021, we anticipate CIMB net product sales landing somewhere between $20 million and $22 million. Throughout 2021, our team has performed very well at stabilizing net sales for our CINV portfolio and the markets where generic competition dominates. As the graph shows, we have largely stabilized CINVANTI net sales and begun growing SUSTOL again after the refresh program we put in place in 2019. As noted on the prior slide, we believe CINV products are set for moderate growth in 2022; on side number 15, we examine SUSTOL more closely. Back in the fourth quarter of 2019, we eliminated all discounting on SUSTOL so that the product's ASP reimbursement could be reset; implementing that process requires five quarters, and after the refresh program, we brought SUSTOL back to growth in 2021, with continued growth expected in 2022. Having finished that quick look at the oncology franchise, I'll hand the call back to Barry now.
Barry Quart
executiveThank you, John, and I'm pleased with how well our launch went during the first quarter. Let me now turn everyone's attention to postoperative nausea and vomiting, or PONV for short. From Heron's standpoint, this is a large and important new market that fits well with the work our commercial group already performs in postoperative pain. The PONV chance is about 20 times bigger than CINV, and HTX-019 delivers substantial advantages over the options available in the market today. We had a productive pre-NDA meeting with the FDA, which got us aligned on the submission we've planned, and we expect to file it during this quarter. If the review takes the standard 10 months, HTX-019 could launch in the fourth quarter of next year, opening the door to potentially several hundred million dollars in sales, including $202.8 million. To demonstrate why this product has us so excited, here's a head-to-head look at two dose levels of aprepitant versus ondansetron, which is the current market leader. What we're showing is the share of patients who had no vomiting after surgery when these agents were given as prophylaxis. I think anybody listening would prefer to be in either of the top two aprepitant arms instead of the ondansetron arm. Each year, roughly 65 million surgical and diagnostic procedures involve patients at risk for PONV, though our attention would go to the high to moderate risk patients shown in the top pie chart. When risk factors are factored in, around 35 million patients a year currently receive prophylaxis for PONV, usually ondansetron. Within that group, those at high to moderate risk should get a second agent, and HTX-019 is a good fit for that. What matters even more are the approximately 5 million patients who undergo surgical procedures where vomiting or retching could interfere with their recovery. That population is a crucial target for HTX-019. Moving into PONV aligns perfectly with Heron's commercial strategy, which rests on two main pillars. The first involves establishing Heron as a leader in acute care. As I said earlier, ZYNRELEF is currently — is clearly off to a fast start and, despite the headwinds, turned in an excellent first quarter of launch. Our agreement with the FDA to expand the label indications once approval is granted will accelerate ZYNRELEF's growth going forward. With the NDA submission for HTX-019 in PONV coming this quarter, we may end up in the enviable position of adding a second commercial product to the acute care franchise in the fourth quarter of next year. That product allows us to get the most from our acute care resources by leveraging the same commercial team and customers. The second pillar of our commercial strategy involves returning to growth and maximizing profitability in the Oncology Care business. In summary, we've stabilized sales in a competitive generic market and are positioned for moderate growth in 2022. Beyond that, we've taken important steps to maximize profitability of our oncology care products. First off, we need to invest in manufacturing CINVANTI at scale, and that should drive COGS significantly lower in 2022. On top of that, we've improved how we align our resources, which lets us maximize profitability, and that brings substantial cost savings with it. You've already heard the commercial numbers from each of our product franchises earlier on today's call. Even so, to wrap up on the financial side, let me quickly walk through those figures once more and provide a bit more detail on our overall financial position. Net product sales for both commercial franchises combined were $23.2 million in Q3 2021, compared with $20 million in the same quarter of 2020, which represents a 16% increase in year-over-year growth. Now for ZYNRELEF, we reported $2.1 million in net product sales for the first quarter of 2021. Regarding CINVANTI, net product sales came to $18 million in the third quarter, versus $19 million — $19.8 million — in the corresponding period of 2020. As for SUSTOL, net product sales were $3.1 million in Q3 2021, compared with $0.2 million in the same period of 2020, and SUSTOL demand units increased 22% versus the previous quarter. Looking toward Q4 2021, we expect net product sales for the Oncology Care franchise to fall somewhere in the range of $20 million to $22 million. And as we enter 2022, we anticipate moderate growth in net product sales. On the operations side, net cash used in operating activities for the 9 months ended September 30, 2021, was $158.1 million, compared with $132.3 million in the same period of 2020. That increase in net cash used in operating activities was primarily driven by working capital changes related to the July 2021 launch of ZYNRELEF, including production of commercial inventory. We expect net cash used in operating activities to be between $45 million and $48 million in the fourth quarter, and we anticipate our net cash usage will continue to decline in 2022 as net product sales grow, and as we realize cost savings from lower expenses in the oncology care franchise as well as from the anticipated large-scale manufacturer. Finally, as of September 30, 2021, our cash, cash equivalents, and short-term investments totaled $2.29 million. Overall, I'm very pleased with the progress we've achieved over the past several months, and we're eager to maintain our momentum through the rest of 2021 as we look forward to a broader commercial opportunity for ZYNRELEF throughout 2022 and continue executing, advancing our oncology care franchise. With that, we're ready to take questions.
Josh Schimmer
analystThanks. I appreciate you taking my question, and I appreciate the thorough overview you gave on the <<inaudible>> metrics. I have a few things to ask. Could you help me grasp why you're generating additional PK and safety data in order to broaden the label for the <<inaudible>> indications? What information will those studies produce that you don't currently possess? Then, regarding the launch that's underway, once you've gotten through those extra P&T committees, where do you anticipate you'll stand at year-end on covered live for hospitals as well as ASCs? And as far as the wins you've been racking up, have they come in settings that tend to be EXPAREL friendly, or ones that aren't friendly? Or would you say it's a combination? Thanks.
Barry Quart
executiveThanks, Josh. I appreciate those questions. Regarding the first one, just to be clear, the initial sNDA we submitted actually had no new information in it, and it was — so it drew on data we had already produced. What we agreed with the FDA was that this data would give us, as I laid out, a broader indication spanning foot and ankle surgical procedures, small to medium open abdominal surgical procedures and lower extremity total arthroplasty. So that's a definite widening of the indication statement. To move past that, the agency wanted to verify that placing the product in other areas of the body wouldn't produce any surprises when it comes to the pharmacokinetics and safety. The agency — and this applies not only to us, it applies to every recently developed locally applied bupivacaine product. They're quite focused on ensuring we hold the risk of last local anesthetic systemic toxicity as low as possible. And they simply want to be sure there are no surprises in the product's pharmacokinetics, because they've said they observed unusually high levels with a previously approved product and they want to confirm ours doesn't do the same; so the agreement is that, given we have the data I just referenced in certain regions, we're going to add to that information and gather data in other regions where we don't currently have any; so that would mean, for instance, shoulder, if you're aiming at a broader (inaudible) both upper and lower extremity, you'd have lower extremity from the currently submitted sNDA, and they're requesting some detailed data in shoulder in order to get across the board, or to plastic; they're seeking data in spine, in order to include a fully broad application — indication for orthopaedics. So that's a significant piece of orthopaedics, and it's also a highly vascular area, so they want to see data in spin. A very nominal amount, but still an important component of what they're seeking. Additionally, we’re engaged in further efforts involving abdominoplasty, which essentially satisfies the requirement for major abdominal procedures; that’s the core reason behind the submission. As I mentioned, the best aspect here is that no randomized efficacy trials are mandated; therefore, the chance of failure is quite low, since we already understand from information gathered to date that bupivacaine is released by our product regardless of vascularity and irrespective of atomic size, and we’ve already completed considerable work in abdominoplasty, plus a highly vascular breast augmentation mammoplasty. Thus, we don’t anticipate observing any atypical drug levels, and we simply have to fulfill that requirement. Those trials are currently underway, and we will gather the data and enable us to file the application during the second half of next year. Now, regarding the second portion of that question, I believe I’ll hand it over to John.
John Poyhonen
executiveYeah, for sure. Hey Josh, I just want to get some clarity on what you asked regarding covered lives. Were you talking about the 88 million covered lives we have right now for separate reimbursement? I just want to make sure I've got your question right.
Josh Schimmer
analystI'm just wondering, what's your outlook for coverage both in hospitals and for ASCs?
John Poyhonen
executiveSure. When it comes to payer mix, we currently have contracts with payers covering roughly 220 million lives, and we're making solid strides adding more. A few of them will essentially be out of reach, since you'd need agreements negotiated at the provider level instead of whatever they can provide; even so, we're pursuing multiple routes to broaden that coverage as much as possible. One approach involves close collaboration with employer coalitions and unions that care deeply about ensuring their workers and workers' families can stay opioid-free after surgery; we're building considerable momentum there. And we expect to keep growing that figure. Right now, I don't feel comfortable providing a particular number, but ensuring ZYNRELEF is available and separately reimbursed with commercial payers across as many ASCs and hospital outpatient settings as we can has become a top priority for us. Your second question, I believe, concerned the P&T committee wins we're securing at present through formulary acceptance; I'd say most of those wins involve accounts where EXPAREL already sits on formulary; that addresses it. One development we're especially enthusiastic about is adding several large hospital systems that have never granted EXPAREL formulary access, and that's truly driven by how strong our clinical data is. They've been running an actual evaluation within some of those hospital systems, and the outcomes have been outstanding; we're thrilled about it, since our ultimate aim isn't merely to replace EXPAREL but also to achieve meaningful progress with bupivacaine so we can hit our targets. Let me know whether that answered your question.
Josh Schimmer
analystI’ll rejoin the queue afterward. Thanks.
Brandon Folkes
analystHello, and thank you for fielding my questions. Nice work on a solid quarter. I’d like to build on what was asked just before. You mentioned securing formulary placement alongside EXPAREL, and I wanted to dig into actual utilization: if you have any input yet, could you say more about whether the product is currently being substituted for generic pivacaine or for other branded options? Then, regarding procedure categories, could you give a little detail on where you’re seeing organic pull, given that you’re promoting to the label, while a number of formularies don’t impose usage restrictions on the product? So are you picking up much off-label use right now, or is it still a bit early? Thanks.
John Poyhonen
executiveBarry, would you like me to handle that?
Barry Quart
executiveYes, please.
John Poyhonen
executiveSo regarding whether we're being utilized — absolutely. If you look at those orthopedic surgeons I mentioned who are using ZYNRELEF in more than 100 TKA cases, every one of them is a hospital-based physician. So it's clear that hospitals are using us. I want to note, and this was included in my prepared remarks, that getting formulary approval is just the initial step — in other accounts, we still haven't achieved usage despite having formulary approval, because you need to get the medical executive sign-off completed, make sure you're working through the computer — the computerized physician order entry — and pharmacy ordering. So there's going to be some pent-up demand out there in the marketplace. But we're very pleased with the usage we're seeing so far. I'm sorry, what was the second question? Could you remind me?
Brandon Folkes
analystRegarding the kinds of procedures, correct? As far as (inaudible) goes, they can use it without restrictions — is everything being utilized (inaudible)? Or are you currently hearing reports of some off-label application?
David Szekeres
executiveYeah. Thanks, Brandon. I'm glad you brought that up. What we've observed is that our promotion is strictly on-label, covering our three indicated procedures. And as I mentioned regarding formulary approval, 55% of hospitals and IDNs that have approved us allow unrestricted use. So anecdotally, we've heard about usage beyond the indicated procedures when surgeons perform a case where representatives are present in the OR, though we can't be involved in that; yet anecdotally we've heard about instances such as orthopedic surgeons achieving good outcomes in TKA, applying it in total hip replacement, and getting very fine results there; but clearly that isn't something we promote. So far, it's all been anecdotal. Barry, I don't know whether you'd like to add anything about that.
Barry Quart
executiveNot at all — honestly, I believe you captured that perfectly. We've obviously been made aware of how the product gets used beyond the 3 surgical procedures covered by the indication, and through medical affairs we do gather that data — our aim was to learn from the favorable experiences people have already had, which could inform any future clinical trials we might run, such as the spine study. That said — and this has come up multiple times now — we obviously do not promote on that basis. Our reps are not permitted in the OR while that type of procedure takes place. Naturally, much of this will shift once the label expansion comes through. We're eager for that, since it will truly unlock the chance for substantial valuable dialogue with surgeons and ultimately secure the best achievable result for patients.
Brandon Folkes
analystThanks a lot.
Boris Peaker
analystThanks. For my next question, I'd like to zero in a bit more on the formulary talks. What I'm wondering is whether you're going head-to-head against EXPAREL. And when these institutions make their decisions, do they wind up picking one product instead of the other, or does it often happen that both EXPAREL and ZYNRELEF get placed on the formulary?
Barry Quart
executiveJohn, would you like to take that one as well?
John Poyhonen
executiveYeah, so thank you — that's really a terrific question, Boris. For the great majority of the accounts that have brought us onto formulary, EXPAREL has in fact stayed on their formulary when it was already there at the start, which connects to what I mentioned in response to the earlier question Josh posed, about how we're indeed picking up both types of accounts: those with EXPAREL on formulary and those without it. Still, none of this comes as a shock. Our intent isn't to see EXPAREL removed from formulary. There are definitely indications for it — pediatrics, for instance, or nerve block — in which ZYNRELEF simply wouldn't be used. So that's perfectly fine by us. What we're aiming for is getting access to the product, delivering a strong experience for surgeons and patients, and driving as much usage as we can; this isn't something we view as either/or. That said, should certain accounts down the road decide to make therapeutic substitutions within label, we would fully support that too.
Barry Quart
executiveYeah. I just want to point out for everybody that when you look at the potential patient population, EXPAREL's penetration is in the single digits. And so — and once again, our goal isn't to try to get them taken off formularies. What we're aiming for is to have our product used in the greatest number of patients possible and to achieve the best possible outcome for those patients. So the fact that they would remain on formulary and especially remain on for those indications — very specific indications such as pediatrics and nerve — but we don't have that, as expected. Hopefully, that addresses your question.
Boris Peaker
analystYes, that definitely helps. My final question concerns the rivals — so you got a C code. Could you speak to the competitive edge that provides? And at what point and in what manner ought we to actually observe that competitive edge developing?
Barry Quart
executiveWell, John, go ahead.
John Poyhonen
executiveOkay, what I meant to say is that the C code was actually set up for the ambulatory surgical center sector, and it takes effect on January 1, 2022. So when it comes to a competitive edge, we'll be in the same spot as other businesses getting reimbursed in that care setting. On top of that, CMS is still reviewing ZYNRELEF for pass-through status, and that's where I think one of the biggest benefits might come from, since pass-through status would deliver reimbursement not just in the ambulatory surgical center setting, but in the hospital outpatient care setting too; and that's an area where EXPAREL, the top branded product, lacks coverage.
Boris Peaker
analystSo when do you think that pass-through designation would come through?
John Poyhonen
executiveThey're still in the process of evaluating what we submitted. So, as I mentioned in my remarks, we're anticipating that at some point in the New Year — typically, they reach their determination roughly 2 to 4 weeks before the quarter wraps up. That means we might get word on the CMS decision as early as early to mid-December.
Barry Quart
executiveJust a quick note for everybody: right now, the share of patients on Medicare that we're going after sits at slightly under 20% for both the ASC and the outpatient hospital setting. That's exactly why the commercial coverage John talked about is such great news and so significant — commercial payers make up the vast majority of patients moving through our two main target areas, outpatient hospital and ASC. But the extended coverage that comes with the C code reaches past the 3 years of standard pass-through. It also matters because it reassures an ASC that might hesitate to bring on a new product when coverage is only temporary; their constant concern is that surgeons will fall in love with a product that's getting reimbursed, and then 3 years down the line, with usage huge, the reimbursement suddenly disappears. So the fact that this is expected to keep going over a longer stretch is genuinely a plus when it comes to getting more ASCs to take on products that have coverage.
Serge Belanger
analystHello, and good afternoon. I have a few questions for you. To start, regarding ZYNRELEF, could you share where you anticipate the product gaining momentum as it begins to scale? Will that be in the ASC environment, HOPDs, or hospitals? Then, you mentioned plans to expand the label — I'm wondering whether a nerve block indication is part of those plans, and if that might come as a separate indication? Thank you.
John Poyhonen
executiveYes, I'll handle the first one, Serge. When it comes to gaining momentum, looking at the initial 160 unique ordering accounts from July through September, those accounts split almost evenly, 50 to 50, in terms of the count of ordering accounts. However, a much larger share of that revenue originated from the hospital setting of care, which makes sense since hospitals clearly carry out many more procedures than ASCs do. Across the entire ASC market, it represents roughly 15% of the procedures we target. That aligns with what we'd anticipate, though ASCs face a lower barrier when it comes to entering and achieving early adoption. I believe that likely addresses your question, Serge, I hope.
Barry Quart
executiveAbsolutely. Regarding the label expansion, the 2 sNDAs we've talked about are solely for local administration, and going forward we don't expect to perform any further nerve block development with ZYNRELEF. The design of ZYNRELEF came from the distinctive synergy observed between bupivacaine and that small quantity of meloxicam, through which we observe markedly improved pain relief even during the initial 24 hours, then persisting through the second 24 and the third 24 hours of use relative to bupivacaine by itself. This happens owing to local inflammation triggered when tissue and bone are cut, producing that localized inflammation, and with ZYNRELEF you get an amplified advantage from the bupivacaine; such a circumstance would not arise in a nerve block context. Consequently, we genuinely forfeit the excellent pharmacology ZYNRELEF offers once it's shifted into a nerve block context. Still, I'd note that, as you might know, our competitor is litigating against ASA over a publication indicating there seemed to be no advantage from EXPAREL compared with bupivacaine in nerve block. Thus, in our view it's entirely sensible simply to employ inexpensive bupivacaine whenever an anesthesiologist judges a nerve block to be necessary. Then use ZYNRELEF applied locally to deliver a considerably longer period of benefit; therefore we consider that the best result, as opposed to attempting to employ an extended release product for the nerve block itself.
Serge Belanger
analystAlright, one brief question about the CINV franchise. You said you anticipate that franchise getting back to growth during 2022. I'm just wondering whether you think it will get back to where it was in 2018 — particularly for CINVANTI — considering the shifts stemming from value-based contracting reimbursement that are reshaping market dynamics?
Barry Quart
executiveJohn?
John Poyhonen
executiveSure, Serge — what we told everyone in today’s guidance is that 2022 should bring moderate growth, and getting back up to those levels would take a substantially bigger increase than what we’d call moderate. With CINVANTI, we see several factors tilting things our way. First, there’s generic fosaprepidence. As I mentioned earlier, reimbursement has dropped to $6.45, so even if they price aggressively for community practices, the value they can deliver isn’t really available. Another important element: once January 1, 2022 arrives, their ASP reimbursement in the hospital market falls so low, and outside the bundled payment there won’t be any reimbursement for generic fosaprepitant. Those two developments together — the effect on the clinic market from the lower ASP and reimbursement, plus zero reimbursement in the hospital market — should let us put Symantec back on a growth path as we go into 2022. I’d anticipate giving a little more guidance on that when we report year-end results and share our view of what 2022 will look like.
Serge Belanger
analystAll right, that's excellent. Thanks.
Kelly Shi
analystI appreciate you fielding my questions. Regarding the $2.1 million in sales during this quarter, could you quantify the split between volume coming from ASC settings and from hospital settings? At present, for the ASC side, is it substantially under 20%? Then, once the C code arrives next year, could you perhaps describe how growth rates would differ between the two settings? Thank you.
John Poyhonen
executiveAll right. Addressing your initial question about ASC volume: that $2.1 million represents what we sold into the distribution channel, while from a demand perspective, roughly 30% during the first quarter came from ASC accounts. As I mentioned previously, unique ordering accounts were split around 50 to 50. That should give you a sense that a larger volume is coming from the hospital marketplace. As for your second question, I wasn't entirely certain what you meant. Would you mind repeating it?
Kelly Shi
analystYes. So what sort of shift do you anticipate regarding the amounts played under SA compared with hospital settings over the coming year?
John Poyhonen
executiveYes. So during that initial quarter, as I mentioned, in terms of actual demand, it was roughly 70 to 30, with 70% coming from the hospital. Looking ahead, we'd anticipate it would normalize more, and likely with over 80% of our business originating in the hospital market and roughly 20% from the ASC market.
Kelly Shi
analystThank you very much.
John Poyhonen
executiveYou’re welcome.
Josh Schimmer
analystI appreciate you letting me come back with a follow-up. I figured out my earlier question on covered lives and hospitals was off base, since that isn't the metric they use. So could you walk through the wins you've had with hospital P&T committees, and where things stand — perhaps as a share of the hospitals you're going after, plus how frequently those P&T decisions will land for the balance of this year and on into 2022?
John Poyhonen
executiveSure. As we laid out earlier today, 126 formulary approvals is the figure. Most of those, in fact, sit with hospital systems. Between today and year-end, Josh, another 150 P&T committees have meetings on the calendar. That should give you an idea of the possible total; our overall target is 1,300 hospitals. The intriguing part about P&T is that each time we refresh this, additional P&T sessions keep appearing. A number of them — which I haven't detailed — already have 2022 dates. Even so, we keep treating it as a top priority. And we'll capture as many as we can. Two things strike me as really encouraging. First, within hospitals our P&T committee approval rate stands at 91%, and second, most of those hospitals are demonstrating relief for unrestricted usage at 55%. Regarding the cadence, though, COVID makes forecasting somewhat difficult. Still, on upcoming earnings calls we'll aim to give updates on our position and what's queued up for the rest of the quarter, so you have a clearer picture.
Josh Schimmer
analystWith a goal of around 1,300 for hospitals, and considering how quickly things have gone so far, is it reasonable to anticipate a pickup in the coming year, or are we simply going to keep grinding our way through that big figure?
John Poyhonen
executiveMy expectation is that we will see a speedup in the coming year, and there are several reasons for that. A few of the P&T committees got delayed as a result of COVID. That, we believe, will assist in moving things along more quickly. Clearly, the earlier we secure the newly indicated procedures, that too, in my view, could speed things up. Additionally, at certain hospitals, they simply default to imposing a hold, stating that they will not assess any products for 6 months until that product has spent 6 months on the market. So when we head into 2022, all of these factors come together in a way that we believe ought to produce a quicker pace regarding formulary approval stress.
Josh Schimmer
analystUnderstood; one final thing regarding this subject. Is this roughly consistent with the 80 to 20 rule, where 20% of hospitals make up 80% of volume, and you target those initially for P&T committees? Or does the dynamic differ somewhat?
John Poyhonen
executiveIf you take a look at the hospitals we are going after, the 1,300 that brings us to roughly 80% of the opportunity, be it competitive products or slightly under that for the indicated procedures, probably 65% to 70%; we always begin with the largest ones, as you might expect. However, at times those bigger ones are slower as well. So we are attempting to be opportunistic. Every one of the 1,300 hospital accounts we are targeting is valuable. And we would gladly accept any of them, yet we start with those possessing the greatest value.
Barry Quart
executiveThere's more than we can handle.
John Poyhonen
executiveIndeed, a few of them are quite large.
Barry Quart
executiveAlright, I appreciate all of you joining us on this call. It was a really thrilling quarter, and we’re eager to keep bringing you updates each quarter. Enjoy the rest of your day.
Operator
operatorEveryone, we've reached the end of this call. Appreciate everyone joining in. You're free to hang up at this point. Farewell.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Heron Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Heron Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Heron Therapeutics, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.